Dr. Michael Brawer discusses the Prolaris score™, which provides a direct measure of individual tumor aggressiveness, and the Prolaris test report, which estimates a patient’s 10-year prostate cancer-specific mortality based upon his unique tumor biology.
Prolaris is important because it provides a more precise prognosis in order to better plan for treatment. In the past, men diagnosed with prostate cancer were often overtreated. However, around 30,000 men will die each year from prostate cancer because they were undertreated. Therefore, knowing the aggressiveness of and individuals prostate cancer is critical to determine the correct prostate cancer treatment plan.
Prolaris is a tissue-based prognostic test that measures the genes within the tumor specimen to determine cell growth. By measuring these genes, Prolaris has proven to provide a much more precise prediction of oncological outcome. In knowing this information, physicians can decide which patients would be good candidates for active surveillance, and which patients should undergo more aggressive treatment.
When Physicians and patients decide to use Prolaris testing, the treatment plan changes from a more aggressive option to a less aggressive option. More than half of the time, patients are able to be placed on active surveillance versus undergoing more aggressive treatment such as surgery. In conclusion, Prolaris has proven to be a better predictor of disease progression and disease-specific mortality when compared to Gleason score and PSA. Results generated from a Prolaris test often give physicians more confidence in making a treatment selection that is right for their patients.
Learn more about the science behind Prolaris from Dr. Michael Brawer.